TRANSVAC (project completed)

European Network of Vaccine Research and Development

Background

Although expertise already exists within Europe spanning different diseases types, there is currently very limited coordination between vaccine Research and Development (R&D) groups, assay developers, and vaccine producers. Unarguably, fragmentation of expertise and facilities has slowed and in some instances distinctly impeded the development and validation of promising vaccines. To address these challenges the European vaccine development community needs to establish a collaborative vaccine development infrastructure based on shared visions and goals.

Despite Europe’s significant vaccine R&D expertise, there is currently a strong need to improve cooperative efforts between R&D groups and vaccine producers across Europe. At present, any R&D group wishing to develop a new experimental vaccine needs to individually locate and approach a fragmented and non-harmonised group of vaccine development service providers.

Objectives:

TRANSVAC is a collaborative infrastructure project funded under the European Commission’s 7th Framework Programme which aims to accelerate the development of promising vaccine candidates by bridging the gap between academic research and clinical trials. In order to reach this goal, TRANSVAC is offering a complimentary set of coordinated vaccine R&D facilities.

The project has emerged as the joint effort of leading European groups in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC’s vaccine development facilities are not linked to any particular type of disease.

up.png back to top

Major Milestones:

TRANSVAC will strengthen collaboration between European vaccine R&D groups, assay developers and vaccine producers, and is addressing the fragmentation of expertise and facilities in vaccine research.

  • RESEARCH - improving the use of assays, adjuvants, animal models, standardised reagents, microarrays and protein expression in relation to the development of experimental vaccines
  • NETWORKING - providing training in vaccine development, harmonising assays, and harmonising microarrays
  • SUPPORT - providing researchers with access to: adjuvant formulation, animal models, microarray analysis, and assays / standards.

Services

The support activities are accessible to research groups across Europe working in vaccine development. They are not restricted to any disease in particular.

Access to Services

Access to TRANSVAC services is for a period of up to three months for organisations fulfilling a simple set of prerequisites:

  • Engagement in vaccine Research and Development
  • The group leader and the majority of scientists on the team work at an institution 
    established in a European Member State or Associated State
  • The group leader and the majority of scientists on the team work in a country other than the country where the infrastructure is to be implemented
  • The organisation is allowed to disseminate the foreground generated during the stay of the team
  • The organisation is complying with the selection criteria described in the following:
    • Description of the work to be carried out on the site in question, and provision of background information supporting the scientific merit of the project;
    • Evaluation by an independent “Scientific Advisory Committee” composed of international experts in vaccine development, by assessing the proposal according to the principles of transparency, fairness and impartiality;
    • Scientific merit and excellence are the main selection criteria.

Publications

Vaccine. 2015 Oct 5;33(41):5481-7. doi: 10.1016/j.vaccine.2015.01.079. Epub 2015 Feb 8
PLOS Neglected Tropical Diseases 2015, May DOI:10.1371/journal.pntd.00037
Sci Rep. 2015 Mar 13;5:9103. doi: 10.1038/srep09103
Vaccine 32, issue 51, 5 December 2014, pages 7021 - 7024
Mol Cell Proteomics. 2014 Oct;13(10):2725-35. doi: 10.1074/mcp.M114.039289. Epub 2014 Jul 21
PLoS One. 2014 Aug 20;9(8):e104824. doi: 10.1371/journal.pone.0104824. eCollection 2014
Vaccine, 32, issue 35, 31 July 2014, 4365 - 4368
Current Opinion in Immunology, 25(4): 441-449.  doi:10.1016/j.coi.2013.05.005
Curr Top Med Chem, 2013; 13 (20): 2562 - 80
Seminars in Immunology, 25(2): 172-181.  doi:10.1016/j.smim.2013.04.006
The Journal of Infectious Diseases, Nov 22, 2013 doi:10.1093/infdis/jit636
Annals of the New York Academy of Sciences, 2013, 1283: 22-29.  doi:10.1111/j.1749-6632.2012.06802.x
Vaccine, 31(9): 1340-1348.  doi:10.1016/j.vaccine.2012.12.053
PLoS Pathog. 2012;8(11):e1003001. doi: 10.1371/journal.ppat.1003001. Epub 2012 Nov 8
Letters in Applied Microbiology, vol. 55, issue 4, 295 - 300 Oct. 2012
Int J Tuberc Lung Dis. 2012 Sep;16(9):1140-8. doi: 10.5588/ijtld.12.0246
Vaccine 2012, 31(9): 1340-1348
Trends Immunol. 2012 Jul;33(7):373-9. doi: 10.1016/j.it.2012.03.004. Epub 2012 May 3
Vaccine, vol. 30, issue 21, 2 May 2012, 3159 - 3168
Microb Biotechnol. 2012 Mar;5(2):168-76. doi: 10.1111/j.1751-7915.2011.00306.x. Epub 2011 Sep 29
Vaccine. 2011 Jul 18;29(32):5210-20. doi: 10.1016/j.vaccine.2011.05.026. Epub 2011 May 25
Vaccine 2011 Jul, Vol. 29 supplement, A37-39
PNAS, 2011, 108 (15) 6217 - 6222